Hypros

What Hypros does

Hypros (legally Shenzhen HaploX Biotechnology Co., Ltd. 深圳市海普洛斯生物科技有限公司) is a precision-medicine and genetic big data company founded in 2014 and headquartered in Shenzhen, China. The company builds and operates the LIUDUS® molecular diagnostics platform — a proprietary low-input, ultra-deep (up to 100,000×), ultra-sensitive (detection limit 0.005%) NGS pipeline centered on three in-house technologies: CUBE-ctDNA single-molecule barcoding (reducing NGS background noise from an industry-average 0.1% to 0.00058%), Effentration® cfDNA extraction, and HAPCap® emulsion-PCR capture. The platform is coupled with in-house bioinformatics (Fastp, GeneFuse, MutScan, FineMSI), a HapLab® LIMS, a HapYun® cloud, and two proprietary clinical knowledge bases — HapKnow (1.4M+ tumor somatic mutations) and HapHeal (1.3M+ hereditary mutations). HaploX also offers a domestic desktop sequencer (HapSeq-2000) and Class III reagent kits for EGFR/ALK and C. difficile detection.

Hypros monetizes across four revenue streams: (i) clinical genetic testing services sold through direct sales to 500+ top-tier Chinese hospitals across 20+ provinces for tumor liquid biopsy, MRD monitoring, and hereditary tumor screening; (ii) pharmaceutical services spanning central laboratory testing, patient recruitment, exploratory research, and companion diagnostics for 100+ pharma clients and 200+ projects; (iii) consumer-facing health-management genetic testing via a WeChat mini-program with home sampling kits and SF Express pickup; and (iv) medical device sales (sequencer, NMPA-approved reagent kits, extraction reagents, and analysis software). The company serves hospital systems, pharmaceutical and biotech companies, research institutes, insurance carriers, local government health programs, and individual consumers in China, with growing international reach via laboratories or subsidiaries in Hong Kong, Singapore, and Japan.

Hypros holds CAP, CLIA, EMQN, NCCL and PQCC certifications, 11 CE-marked products as of 2025, multiple NMPA Class III approvals, and operates six regional testing laboratories. It is led by co-founder Dr. Xu Mingyan (Chairman and CEO) and co-founder Dr. Chen Shifu (CTO, top-2% scientist 2022-2025), backed through Series D funding from angel to domestic Series D since 2015. Key strategic risks include regulatory exposure, dependency on hospital procurement budgets, and competitive intensity in Chinese precision oncology against larger platform players.

Name

Hypros

Legal name

深圳市海普洛斯生物科技有限公司

Website

https://haplox.cn

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Hypros (HaploX) is a Shenzhen-headquartered precision-medicine company that operates a proprietary NGS-based liquid biopsy platform to deliver tumor liquid biopsy, MRD monitoring, and hereditary cancer testing to 500+ top-tier Chinese hospitals and 100+ pharmaceutical clients.

Ownership category

akta.pro rank

Product category

Precision Oncology Genetic Testing Services

NAICS

Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Lab Data Exchange & Interoperability (HL7/FHIR/LDT Results Delivery) (HLACAMAL), Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC)

Keywords

• Precision oncology diagnostics
• Liquid biopsy services
• Clinical genetic testing
• NGS sequencing platform
• Companion diagnostics

Headquarters

HQ city

Shenzhen

HQ country

China

HQ region

Asia

Offices9 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Genetic Testing Services: Revenue from comprehensive genetic testing services including tumor liquid biopsy, MRD detection, hereditary tumor screening, covering the full cancer disease management cycle. Services provided to top-tier hospitals, research institutes, and directly to patients.
2. Pharmaceutical Services: Revenue from serving pharmaceutical companies including central laboratory testing, patient recruitment, exploratory research, and companion diagnostics development. Has served 100+ pharma clients with 200+ projects completed.
3. Health Management Services: Consumer-facing genetic testing products for health management including whole genome screening, carrier screening, cardiovascular health, cancer risk assessment, and precision weight management.
4. Medical Device Sales: Sales of medical devices including HapSeq-2000 gene sequencer, EGFR/ALK mutation detection kits (Class III medical device), nucleic acid extraction reagents, and non-small cell lung cancer gene variant analysis software.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Hypros operates a precision oncology and genetic testing platform spanning clinical diagnostics, pharmaceutical research services, consumer health, and medical devices. It delivers tumor liquid biopsy, MRD monitoring, hereditary cancer screening, and pharmacogenomic testing to 500+ Chinese hospitals through direct sales, while also offering centralized lab testing and companion diagnostics to 100+ pharmaceutical companies and consumer genetic testing via a WeChat mini-program. Proprietary NGS technology (LIUDUS® platform) and the HapSeq-2000 sequencer anchor the integrated BT+IT service stack.

Differentiator

Problem solved

Functional benefit

Brands

• LIUDUS®: 分子诊断技术平台（Low-input, Ultra-deep, Ultra-sensitive），整合分子技术、生物信息工具和集成应用
• HapLab®
• HapYun®
• HapSeq-2000
• 海普鲲®
• 海普星®
• 海微清®
• 海微净®
• 海普康®
• 海普因™
• HapOnco®
• Haplife
• 海普惠®
• 海普安可®
• 帕利安®
• 融逸宁®

Products and services

• Clinical Tumor Genetic Testing Services Comprehensive clinical genetic testing for cancer patients covering tumor molecular profiling, minimal residual disease detection, hereditary tumor screening, and treatment guidance; delivered to 500+ top-tier Chinese hospitals through direct sales.
• Pharmaceutical Services (Central Lab Testing & Companion Diagnostics) Central laboratory testing, patient recruitment, exploratory biomarker research, and companion diagnostics development for pharmaceutical and biotech companies conducting oncology drug development.
• Consumer Health Genetic Testing

Quantifiable outcome

• ctDNA detection limit as low as 0.005% (100,000X sequencing depth)
• +3 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration20 records

AI capability12 records

Feature7 records

Partnerships

Four partnerships are on record, tiered core.

• 深圳泛因医学有限公司 (Fann Medical)coreStrategic or Co-development Partner · 22 September 2025Strategic partnership announced September 22, 2025 for immuneomics testing services. Fann Medical is a professional immunology testing services company, and HaploX is a national high-tech enterprise and specialized, refined, novel, and high-tech small giant enterprise in precision medicine and genetic big data. The partnership aims to jointly open a new chapter in precision medicine.
• BGI (华大基因)coreTechnology or IntegrationPartnership for spatiotemporal omics services including BGI Stereo-seq spatial transcriptomics, BGI FFPE spatial transcriptomics, and BGI spatial proteomics. Uses BGI's proprietary DNBSEQ sequencing technology and Stereo Chip spatial capture technology.
• 10X GenomicscoreTechnology or IntegrationPartnership for single-cell sequencing services using 10X Genomics platforms including Chromium and Visium spatial transcriptomics solutions.
• IlluminacoreTechnology or IntegrationPlatform partnership for sequencing services using Illumina platforms including NovaSeq 6000, NovaSeq X Plus, NextSeq 550, and HiSeq X for various genomic applications.

Scale indicators7 records

Recent moves15 records

Expansion highlights6 records

Direct peers

• BGI Genomics: China's largest NGS services and sequencing platform provider; directly competes with Hypros in clinical NGS testing, liquid biopsy, and oncology diagnostics, and is a sequencing hardware supplier to Hypros through DNBSEQ platforms.
• Novogene: Leading Chinese NGS services company serving research institutes, hospitals, and pharma; directly comparable to Hypros in genomic/transcriptomic services, single-cell, and spatial omics offerings.
• Burning Rock Biotech: China-based oncology NGS company specializing in tumor genetic testing, MRD, and companion diagnostics; direct competitor in cancer-focused liquid biopsy and CDx services.
• Geneseeq Technology: Chinese oncology NGS company offering ctDNA-based liquid biopsy panels and companion diagnostics; comparable in target customer (top hospitals and pharma) and technology focus.
• Berry Genomics: Chinese genetic testing company with strong presence in reproductive health, hereditary disease, and tumor diagnostics; competes in hospital-channel genetic testing and NIPT-adjacent services.

Broad incumbents

• Guardant Health: Global leader in liquid biopsy and oncology genomics; broader test menu and stronger pharma CDx relationships make it a relevant international comparable and competitor for cross-border pharma wins.
• Foundation Medicine: Roche-owned leader in comprehensive genomic profiling for oncology; comparable as a hospital- and pharma-facing CGP/CDx player and a benchmark for Hypros's pharma services ambitions.
• Illumina: Dominant NGS platform supplier and increasingly a clinical diagnostics competitor; comparable as the sequencing technology backbone Hypros uses and as a long-term competitor in clinical NGS.
• WuXi AppTec: China-headquartered global CRO/CDMO with central laboratory services for pharma clinical trials; comparable on the pharma services side, particularly central lab and biomarker testing.

Regional players

• Kingmed Diagnostics: China's largest independent medical diagnostics network; comparable in operating medical testing laboratories at scale and serving top-tier hospitals, though broader than oncology.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hypros